KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Capital Expenditures (2016 - 2025)

CRISPR Therapeutics AG's Capital Expenditures history spans 11 years, with the latest figure at $517000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 134.63% year-over-year to $517000.0; the TTM value through Dec 2025 reached $914000.0, up 493.51%, while the annual FY2025 figure was $914000.0, 493.51% up from the prior year.
  • Capital Expenditures for Q4 2025 was $517000.0 at CRISPR Therapeutics AG, up from $74000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $65.0 million in Q3 2021 and bottomed at -$20.1 million in Q3 2022.
  • The 5-year median for Capital Expenditures is $612000.0 (2024), against an average of $6.0 million.
  • The largest annual shift saw Capital Expenditures skyrocketed 1840.93% in 2021 before it plummeted 5232.14% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $9.2 million in 2021, then surged by 251.4% to $32.3 million in 2022, then crashed by 100.09% to -$28000.0 in 2023, then tumbled by 5232.14% to -$1.5 million in 2024, then soared by 134.63% to $517000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Capital Expenditures are $517000.0 (Q4 2025), $74000.0 (Q3 2025), and $117000.0 (Q2 2025).